Specifically speaking of lung adenocarcinoma, genetic and molecular analysis is increasingly performed to determine EGFR mutation positivity in order to direct to EGFR tyrosine kinase inhibitor (TKI) treatment, whereby the third generation EGFR-TKI (osimertinib) is actively being researched in combination with the intravitreal bevacizumab [16]. This evidence concerns the gene EGFR and lung adenocarcinoma.